Linked e-resources
Details
Table of Contents
Foreword; Preface; Acknowledgements; Contents; Contributors; 1: Hepatobiliary and Pancreatic Malignancies: Epidemiology, Clinical Presentation, Diagnosis, and Staging; 1.1 Introduction; 1.2 Hepatocellular Carcinoma; 1.2.1 Epidemiology and Etiology; 1.2.2 Clinical Presentation; 1.2.3 Diagnosis and Staging; 1.3 Carcinoma of the Gall Bladder and Bile Ducts; 1.3.1 Epidemiology and Etiology; 1.3.2 Clinical Presentation; 1.3.3 Diagnosis and Staging; 1.4 Pancreatic Carcinoma; 1.4.1 Epidemiology and Etiology; 1.4.2 Clinical Presentation; 1.4.3 Diagnosis and Staging; References
2: Pathology of Hepatobiliary and Pancreatic Cancer2.1 Introduction; 2.2 Gall Bladder; 2.3 Pancreatic Carcinoma; References; 3: Management of Hepatobiliary and Pancreatic Malignancies; 3.1 Introduction; 3.2 Management of HCC; 3.3 Management of Cancers of the Gall Bladder and Bile Duct; 3.3.1 Surgery: Gall Bladder Cancer; 3.3.2 Surgery: Cholangiocarcinoma; 3.3.3 Adjuvant Therapy: Gall Bladder Cancer; 3.3.4 Adjuvant Therapy: Cholangiocarcinoma; 3.3.5 Unresectable Disease: Gall Bladder Cancer and Cholangiocarcinoma; 3.4 Management of Pancreatic Cancer; References
4: Radiological Imaging in Hepatobiliary and Pancreatic Malignancies4.1 Gall Bladder Carcinoma; 4.2 Pancreatic Carcinoma; References; 5: FDG PET/CT: Normal Variants, Artefacts and Pitfalls in Hepatobiliary and Pancreatic Malignancies; 5.1 Introduction; 5.2 Variations in Imaging Appearance Due to Anatomy and Histology; 5.3 Inflammatory Pathology Mimicking Malignancy; 5.4 Pitfalls Due to Treatment-Related Changes and Complications; References; 6: Hepatic Malignancies and FDG PET/CT; 6.1 Hepatocellular Carcinoma; 6.1.1 Staging; 6.1.2 Treatment Response Assessment
6.1.3 Utility of PET/CT in Evaluating Radioembolization of HCC6.1.4 Disease Recurrence; 6.2 Hepatoblastomas; References; 7: PET/CT in Pancreatic Malignancies; 7.1 Introduction; 7.2 Imaging Modalities in Pancreatic Cancer; 7.3 PET/CT in Pancreatic Cancer; 7.3.1 Diagnosis and Staging; 7.3.2 Local Staging; 7.3.3 Nodal Staging; 7.4 Liver Metastases; 7.5 Other Distant Metastases; 7.6 PET/CT to Detect Disease Recurrence; 7.7 PET/CT to Detect Treat Response; 7.8 PET Tracers for Other Pancreatic Neoplasms; 7.8.1 68Ga-DOTA-PET/CT; 7.8.2 68Ga-DOTA-Exendin-4 PET/CT
7.8.3 18F-FDOPA PET/CTReferences; 8: PET/CT in Gall Bladder and Biliary Tract Malignancies; 8.1 Gall Bladder Cancer; 8.2 Conventional Imaging Modalities for Diagnosis and Staging of Gall Bladder Cancer; 8.3 Role of FDG PET/CT in the Evaluation of Gall Bladder Malignancies; 8.4 Role of FDG PET/CT in Prognostication; 8.5 Cholangiocarcinoma; 8.6 Role of Conventional Imaging Modalities; 8.7 Role of 18F-FDG PET in Diagnosis of the Primary Lesion; 8.8 Role of 18F-FDG PET in Detection of Lymph Nodal Metastases; 8.9 Role of 18F-FDG PET in Detection of Distant Metastases; References; Index
2: Pathology of Hepatobiliary and Pancreatic Cancer2.1 Introduction; 2.2 Gall Bladder; 2.3 Pancreatic Carcinoma; References; 3: Management of Hepatobiliary and Pancreatic Malignancies; 3.1 Introduction; 3.2 Management of HCC; 3.3 Management of Cancers of the Gall Bladder and Bile Duct; 3.3.1 Surgery: Gall Bladder Cancer; 3.3.2 Surgery: Cholangiocarcinoma; 3.3.3 Adjuvant Therapy: Gall Bladder Cancer; 3.3.4 Adjuvant Therapy: Cholangiocarcinoma; 3.3.5 Unresectable Disease: Gall Bladder Cancer and Cholangiocarcinoma; 3.4 Management of Pancreatic Cancer; References
4: Radiological Imaging in Hepatobiliary and Pancreatic Malignancies4.1 Gall Bladder Carcinoma; 4.2 Pancreatic Carcinoma; References; 5: FDG PET/CT: Normal Variants, Artefacts and Pitfalls in Hepatobiliary and Pancreatic Malignancies; 5.1 Introduction; 5.2 Variations in Imaging Appearance Due to Anatomy and Histology; 5.3 Inflammatory Pathology Mimicking Malignancy; 5.4 Pitfalls Due to Treatment-Related Changes and Complications; References; 6: Hepatic Malignancies and FDG PET/CT; 6.1 Hepatocellular Carcinoma; 6.1.1 Staging; 6.1.2 Treatment Response Assessment
6.1.3 Utility of PET/CT in Evaluating Radioembolization of HCC6.1.4 Disease Recurrence; 6.2 Hepatoblastomas; References; 7: PET/CT in Pancreatic Malignancies; 7.1 Introduction; 7.2 Imaging Modalities in Pancreatic Cancer; 7.3 PET/CT in Pancreatic Cancer; 7.3.1 Diagnosis and Staging; 7.3.2 Local Staging; 7.3.3 Nodal Staging; 7.4 Liver Metastases; 7.5 Other Distant Metastases; 7.6 PET/CT to Detect Disease Recurrence; 7.7 PET/CT to Detect Treat Response; 7.8 PET Tracers for Other Pancreatic Neoplasms; 7.8.1 68Ga-DOTA-PET/CT; 7.8.2 68Ga-DOTA-Exendin-4 PET/CT
7.8.3 18F-FDOPA PET/CTReferences; 8: PET/CT in Gall Bladder and Biliary Tract Malignancies; 8.1 Gall Bladder Cancer; 8.2 Conventional Imaging Modalities for Diagnosis and Staging of Gall Bladder Cancer; 8.3 Role of FDG PET/CT in the Evaluation of Gall Bladder Malignancies; 8.4 Role of FDG PET/CT in Prognostication; 8.5 Cholangiocarcinoma; 8.6 Role of Conventional Imaging Modalities; 8.7 Role of 18F-FDG PET in Diagnosis of the Primary Lesion; 8.8 Role of 18F-FDG PET in Detection of Lymph Nodal Metastases; 8.9 Role of 18F-FDG PET in Detection of Distant Metastases; References; Index